Grundlæggende statistik
| LEI | 529900MITZTZ3CAQTN62 |
| CIK | 840551 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Titan Medical Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 333-225962 Titan Medical Inc. (Exact name of registrant as specified in its |
|
| April 5, 2023 |
April 4, 2023 Jasminder Brar Vice President, Legal & IP, & General Counsel Titan Medical Inc. |
|
| April 5, 2023 |
Securities and Exchange Commission AW 1 ea176524-awtitanmedical.htm AMENDMENT WITHDRAWAL Jasminder Brar Vice President, Legal & IP, & General Counsel Titan Medical Inc. April 4, 2023 416.628.6875 Direct [email protected] Via EDGAR Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 USA Re: Titan Medical Inc. Request to Withdraw Post-Effective Amendment to Form S-8 (File No. 333-240018) Ladie |
|
| April 5, 2023 |
Securities and Exchange Commission Jasminder Brar Vice President, Legal & IP, & General Counsel Titan Medical Inc. April 4, 2023 416.628.6875 Direct [email protected] Via EDGAR Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 USA Re: Titan Medical Inc. Request to Withdraw Post-Effective Amendment to Form S-8 (File No. 333-229612) Ladies and Gentlemen: Pursuant to Rule 477 of the Securitie |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 5, 2023 |
Securities and Exchange Commission Jasminder Brar Vice President, Legal & IP, & General Counsel Titan Medical Inc. April 4, 2023 416.628.6875 Direct [email protected] Via EDGAR Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 USA Re: Titan Medical Inc. Request to Withdraw Post-Effective Amendment to Form S-8 (File No. 333-267447) Ladies and Gentlemen: Pursuant to Rule 477 of the Securitie |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 5, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
Titan Medical Announces Receipt of MCTO EXHIBIT 99.1 Titan Medical Announces Receipt of MCTO TORONTO, ON, April 04, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announces that it has been granted a management cease trade order (“MCTO”) by the Ontario Securities Commission (the “OSC”), as its principal regulator, under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure De |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 POS AM 1 ea176405-posamtitanmed.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. 333-266994 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TITAN MEDICAL INC. (Exact name of registrant as spec |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 As filed with the Securities and Exchange Commission on April 3, 2023 Registration No. |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-38524 Titan Medical Inc. The NASDAQ Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange |
|
| April 3, 2023 |
Titan Medical Provides Corporate Update EXHIBIT 99.1 Titan Medical Provides Corporate Update TORONTO, ON, April 03, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today provided an update on its annual filings and certain other corporate and operational matters. On March 22, 2023, the Company announced that it would not be filing its annual financial statements, the related management’s disc |
|
| April 3, 2023 |
6-K 1 f6k040323.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canad |
|
| March 23, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change March 22, 2023 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on March 22, 2023, through GlobeNewswire. The news r |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 22, 2023 |
Titan Medical Announces Delays in its Annual Filings and Planned Deregistration with the SEC EdgarFiling EXHIBIT 99.1 Titan Medical Announces Delays in its Annual Filings and Planned Deregistration with the SEC TORONTO, ON, March 22, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today announces that, as a result of certain financial and operational challenges that the Company has experienced over the past several months and as a result of the |
|
| March 22, 2023 |
6-K 1 f6k032223.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canad |
|
| March 9, 2023 |
EdgarFiling EXHIBIT 99.1 Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares Common shares to continue to trade on the Toronto Stock Exchange and are expected to trade on the OTC Markets TORONTO, ON, March 09, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today announced that it has received a decision of the Nasdaq Hea |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 9, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change March 9, 2023 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on March 9, 2023, through GlobeNewswire. The news rel |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change December 6, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on December 6, 2022, through GlobeNewswire. The ne |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change February 14, 2023 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on February 14, 2023, through GlobeNewswire. The |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change September 22, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on September 22, 2022, through GlobeNewswire. Th |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change September 26, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on September 26, 2022, through GlobeNewswire. Th |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change November 30, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on November 30, 2022, through GlobeNewswire. The |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change September 12, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on September 12, 2022, through GlobeNewswire. Th |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change December 13, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on December 13, 2022, through GlobeNewswire. The |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change December 28, 2022 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on December 28, 2022, through GlobeNewswire. The |
|
| March 7, 2023 |
6-K 1 f6k030623.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canad |
|
| March 7, 2023 |
6-K 1 f6k030623.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canad |
|
| March 7, 2023 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the “Company” or “Titan”) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change February 8, 2023 Item 3 News Release Attached as Schedule “A” is a copy of a news release relating to a material change, which was disseminated on February 8, 2023, through GlobeNewswire. The ne |
|
| February 14, 2023 |
EXHIBIT 99.1 Titan Medical Announces Executive Leadership Updates and Receipt of Nasdaq Notification Regarding Audit Committee Requirements Toronto, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Depart |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| February 8, 2023 |
EXHIBIT 99.1 Titan Medical Provides Corporate Update Announces Further Costing Reduction Activities and Updates to Strategic Review Process TORONTO, Feb. 08, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today provided an update on the previously announced review and evaluation of strategic alternatives. As previously disclosed on November 30, 2022, |
|
| January 9, 2023 |
6-K 1 f6k010923.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkeley Street Toronto, Ontario M5A 2W7 Can |
|
| January 9, 2023 |
EXHIBIT 99.1 Titan Medical Shares Latest Technology Innovation and Announces Meeting Participation During J.P. Morgan Healthcare Conference Week TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today an |
|
| December 28, 2022 |
Titan Medical Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing EXHIBIT 99.1 Titan Medical Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing TORONTO, ON, Dec. 28, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (the ?Company?), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that, on Dec |
|
| December 28, 2022 |
6-K 1 f6k122822.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Can |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| December 13, 2022 |
EXHIBIT 99.1 Titan Medical Granted Patent Covering User Experience, Further Enhancing its Intellectual Property in Robotic Assisted Surgery TORONTO, ON, Dec. 13, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today ann |
|
| December 7, 2022 |
EXHIBIT 99.1 Titan Medical Suspends Special Meeting of Shareholders in Conjunction with Initiation of Strategic Review Process TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that in view of the commencement of the strategic review process announced on Novemb |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| December 6, 2022 |
Titan Medical Implements Cost-Cutting Measures to Support Strategic Review Process EXHIBIT 99.1 Titan Medical Implements Cost-Cutting Measures to Support Strategic Review Process TORONTO, ON, Dec. 06, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will implement certain cost-cutting measures with a view to preserving capital to support th |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| November 30, 2022 |
Titan Medical Announces Commencement of Strategic Review Process EdgarFiling EXHIBIT 99.1 Titan Medical Announces Commencement of Strategic Review Process TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (“Titan” or the “Company”), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that its Board of Directors (or the “Board”), in consultation with its financial and legal adv |
|
| November 17, 2022 |
EXHIBIT 99.1 Titan Medical Announces American Association of Gynecologic Laparoscopy Global Congress Participation TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congres |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| November 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Cary G. Vance, President and Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Ba |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| November 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Stephen Lemieux, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Based on my kn |
|
| November 10, 2022 |
Exhibit 99.1 Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting Shareholder Meeting to Support Share Consolidation to Maintain Nasdaq Listing TORONTO, November 10, 2022 - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single acce |
|
| November 10, 2022 |
Exhibit 99.2 ? Q3 2022 Condensed Interim Consolidated Financial Statements (Unaudited) Condensed Interim Consolidated Statements of Financial Position (Unaudited) (In thousands of US dollars) As at September 30, 2022 As at December 31, 2021 Notes $ $ ASSETS CURRENT ASSETS Cash and cash equivalents 11,636 32,306 Accounts receivable - 8,280 Prepaid expenses, deposits and receivables 2,367 3,076 TOTA |
|
| November 10, 2022 |
Nine Months Ended September 30, Exhibit 99.3 TITAN MEDICAL INC. Management?s Discussion and Analysis for the three and nine months ended September 30, 2022 November 9, 2022 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 OVERVIEW 4 SIGNIFICANT TRANSACTIONS 5 ENOS SINGLE ACCESS ROBOTIC ASSISTED SURGICAL SYSTEM 7 INTELLECTUAL PROPERTY AND LICENSING 13 RESULTS OF OPERATIONS 13 FINANCIAL POSIT |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exe |
|
| November 2, 2022 |
EXHIBIT 99.1 Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022 Webcast to Follow Announcement TORONTO, ON, Nov. 02, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its third quarter 2022 financial results prior to |
|
| September 26, 2022 |
EXHIBIT 99.1 Titan Medical Announces Appointment of Eric Heinz as Vice President, Market and Corporate Development TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz h |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 22, 2022 |
EXHIBIT 99.1 Titan Medical Announces Publication of Patent Application Expanding Commitment to Continued Innovation in Single Access Robotic Assisted Surgery Strengthens company?s intellectual property portfolio with innovations in next generation single access RAS technology TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Titan Medical Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 98-0663504 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 76 Berkeley Street Toronto, Ontario M5A 2W7 Canada (Address of |
|
| September 16, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) TITAN MEDICAL INC. |
|
| September 12, 2022 |
EXHIBIT 99.1 Titan Medical Signs Definitive Agreement with Medtronic Titan to support Medtronic development and pre-clinical activities through supply of instruments and cameras TORONTO, Sept. 12, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access roboti |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 9, 2022 |
Exhibit 99.1 TITAN MEDICAL INC. SHARE UNIT PLAN ARTICLE 1 RECITALS 1. Purpose . Titan Medical Inc. (together with any successor thereto, the “ Corporation ”) wishes to establish this Titan Medical Inc. Share Unit Plan (the “ Plan ”) in order to: (a) encourage selected Eligible Employees and Service Providers of the Corporation and its Affiliates to: (i) acquire a proprietary interest in the growth |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 9, 2022 |
TITAN MEDICAL INC. STOCK OPTION PLAN (Amended and Restated effective as of June 9, 2021) Exhibit 99.1 TITAN MEDICAL INC. STOCK OPTION PLAN (Amended and Restated effective as of June 9, 2021) 1. The Plan and Definitions A stock option plan (this ?Plan?), pursuant to which options to purchase common shares in the capital of Titan Medical Inc. (the ?Corporation?) may be granted to the directors, officers and employees of the Corporation and to Service Providers retained by the Corporatio |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 9, 2022 |
TITAN MEDICAL INC. DEFERRED SHARE UNIT PLAN ARTICLE 1 INTRODUCTION Exhibit 99.1 TITAN MEDICAL INC. DEFERRED SHARE UNIT PLAN ARTICLE 1 INTRODUCTION 1.1 Purpose The purpose of this Deferred Share Unit Plan is to provide directors of Titan Medical Inc. (the ?Corporation?) with the opportunity to acquire Deferred Share Units (as defined herein) of the Corporation in order to allow them to participate in the long-term success of the Corporation and to promote a greate |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal ex |
|
| September 9, 2022 |
Exhibit 99.1 TITAN MEDICAL INC. EMPLOYEE SHARE PURCHASE PLAN June 8, 2022 2 EMPLOYEE SHARE PURCHASE PLAN Article 1 Purpose 1. This document constitutes the Employee Share Purchase Plan of Titan Medical Inc. 2. The purpose of this Plan is to provide an opportunity for Participants to invest in Equity Shares through savings in the form of Contributions . 3. The Plan is comprised of two components : |
|
| September 6, 2022 |
6-K 1 f6k090222.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Ca |
|
| September 6, 2022 |
Titan Medical to Present at the H.C. Wainwright Global Investment Conference EXHIBIT 99.1 Titan Medical to Present at the H.C. Wainwright Global Investment Conference TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos? robotic single access surgical system at the H.C. Wainwright Gl |
|
| August 23, 2022 |
August 23, 2022 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 19, 2022 |
EX-FILING FEES 4 exh107.htm CALCULATION OF FILING FEE TABLES EX-FILING FEES Calculation of Filing Fee Tables FORM F-3 (Form Type) TITAN MEDICAL INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximu |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TITAN MEDICAL INC. (Exact name of registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) Ontario, Canada (State of incorporation or organization) 98-0663504 (I.R.S. Employer Identification No.) 76 Berkeley Street To |
|
| August 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Stephen Lemieux, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based on my knowled |
|
| August 11, 2022 |
Exhibit 99.2 Q2, 2022 Condensed Interim Consolidated Financial Statements (Unaudited) Condensed Interim Consolidated Statements of Financial Position (Unaudited) (in thousands of US dollars) As at June 30, 2022 As at December 31, 2021 Notes $ $ ASSETS CURRENT ASSETS Cash and cash equivalents 20,179 32,306 Accounts receivable - 8,280 Prepaid expenses, deposits and receivables 1,517 3,076 TOTAL CURR |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execu |
|
| August 11, 2022 |
Exhibit 99.1 Titan Medical Reports Financial Results for the Second Quarter 2022 New CEO Appointed, Manufacturing Progress Noted TORONTO, August 11, 2022 - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results for t |
|
| August 11, 2022 |
EX-99.3 4 exhibit99-3titan.htm MDA Exhibit 99.3 TITAN MEDICAL INC. Management’s Discussion and Analysis for the three and six months ended June 30, 2022 August 10, 2022 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 OVERVIEW 4 SIGNIFICANT TRANSACTIONS 5 ENOS SINGLE ACCESS ROBOTIC ASSISTED SURGICAL SYSTEM 7 INTELLECTUAL PROPERTY AND LICENSING 12 RESULTS OF O |
|
| August 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Cary G. Vance, President and Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based o |
|
| July 29, 2022 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the ?Company? or ?Titan?) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change June 28, 2022 Item 3 News Release Attached as Schedule ?A? is a copy of a news release relating to a material change, which was disseminated on June 28, 2022, through GlobeNewswire. The news rel |
|
| July 29, 2022 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the ?Company? or ?Titan?) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change June 30, 2022 Item 3 News Release Attached as Schedule ?A? is a copy of a news release relating to a material change, which was disseminated on June 30, 2022, through GlobeNewswire. The news rel |
|
| July 29, 2022 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the ?Company? or ?Titan?) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change June 29, 2022 Item 3 News Release Attached as Schedule ?A? is a copy of a news release relating to a material change, which was disseminated on June 29, 2022, through GlobeNewswire. The news rel |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 29, 2022 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the ?Company? or ?Titan?) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change June 1, 2022 Item 3 News Release Attached as Schedule ?A? is a copy of a news release relating to a material change, which was disseminated on June 1, 2022, through Business Wire. The news relea |
|
| July 29, 2022 |
MATERIAL CHANGE REPORT Form 51-102F3 Exhibit 99.1 MATERIAL CHANGE REPORT Form 51-102F3 Item 1 Name and Address of Company Titan Medical Inc. (the ?Company? or ?Titan?) 76 Berkeley Street Toronto, Ontario M5A 2W7 Item 2 Date of Material Change December 1, 2021 Item 3 News Release Attached as Schedule ?A? is a copy of a news release relating to a material change, which was disseminated on December 1, 2021, through Business Wire. The ne |
|
| July 25, 2022 |
EXHIBIT 99.1 Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022 Webcast to Follow Announcement TORONTO, July 25, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its second quarter 2022 financial results prior to mark |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 22, 2022 |
Exhibit 99.1 76 Berkeley Street Toronto, Ontario, Canada M5A 2W7 ? Tel: 416.548.7522 [email protected] ? www.titanmedicalinc.com NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 8, 2022 AND MANAGEMENT INFORMATION CIRCULAR DATED APRIL 27, 2022 These materials are important and require your immediate attention. They require shareholders of Titan Medical Inc. to make imp |
|
| July 22, 2022 |
Exhibit 99.2 |
|
| July 22, 2022 |
Exhibit 99.4 8 th Floor, 100 University Avenue Toronto, Ontario M 5 J 2 Y 1 www . computershare . com Form of Proxy - Annual and Special Meeting of Shareholders to be held on June 8th, 2022 01TU3B Fold Fold This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a holder, t |
|
| July 22, 2022 |
Exhibit 99.3 June 8, 2022, 4:00 p.m. (Eastern Time) The Meeting will be held virtually at https://web.lumiagm.com/432237190 password: titan2022 (case sensitive) The Meeting Materials and other relevant information are available on: Our website at www.titanmedicalinc.com On SEDAR at www.sedar.com The Circular and this notice will remain available on our website for one year after the date of this n |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| July 21, 2022 |
6-K 1 f6k072022.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada |
|
| July 21, 2022 |
TITAN MEDICAL INC. EMPLOYEE SHARE PURCHASE PLAN June 8, 2022 EMPLOYEE SHARE PURCHASE PLAN Exhibit 99.1 TITAN MEDICAL INC. EMPLOYEE SHARE PURCHASE PLAN June 8, 2022 EMPLOYEE SHARE PURCHASE PLAN Article 1 Purpose 1.1 This document constitutes the Employee Share Purchase Plan of Titan Medical Inc. 1.2 The purpose of this Plan is to provide an opportunity for Participants to invest in Equity Shares through savings in the form of Contributions. 1.3 The Plan is comprised of two components: a |
|
| June 30, 2022 |
Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer EXHIBIT 99.1 Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer TORONTO, June 30, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Cary G. Vance has been ap |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 29, 2022 |
Titan Medical Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule EXHIBIT 99.1 Titan Medical Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule TORONTO, June 29, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that the Listing Qualific |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 28, 2022 |
EXHIBIT 99.1 Titan Medical Provides Update to Enos Project Timeline De Novo marketing authorization planned for early 2025 remains unchanged TORONTO, June 28, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announ |
|
| June 28, 2022 |
6-K 1 f6k062822.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada |
|
| June 23, 2022 |
Titan Medical to Participate at the Society of Robotic Surgery Annual Meeting EXHIBIT 99.1 Titan Medical to Participate at the Society of Robotic Surgery Annual Meeting TORONTO, June 23, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced its participation at this year’s Society of Ro |
|
| June 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 21, 2022 |
Titan Medical Announces Agreement with Nissha Medical Technologies EXHIBIT 99.1 Titan Medical Announces Agreement with Nissha Medical Technologies TORONTO, ON, June 21, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that it has signed an agreement with Nissha Medical T |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 10, 2022 |
TITAN MEDICAL INC. ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS June 8, 2022 REPORT OF VOTING RESULTS EXHIBIT 99.1 TITAN MEDICAL INC. ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS June 8, 2022 REPORT OF VOTING RESULTS Pursuant to section 11.3 of National Instrument 51-102 ? Continuous Disclosure Obligations, the following matters were put to a vote at the annual and special meeting (the ?Meeting?) of the shareholders of Titan Medical Inc. (the ?Corporation?) held on June 8, 2022 and the report on the |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 10, 2022 |
Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders EXHIBIT 99.1 Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders TORONTO, June 09, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the voting results form the company’s A |
|
| June 6, 2022 |
Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations EXHIBIT 99.1 Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations TORONTO, June 06, 2022 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the appointment of Bill Fahey as Vice Pres |
|
| June 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| June 1, 2022 |
Titan Medical Announces Executive Departure EX-99.1 2 a52735870ex991.htm EXHIBIT 99.1 Exhibit 99.1 Titan Medical Announces Executive Departure TORONTO-(BUSINESS WIRE)-June 1, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced, after careful consideration and a review o |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executi |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executiv |
|
| May 18, 2022 |
Titan Medical to Present at the H.C. Wainwright Global Investment Conference Exhibit 99.1 Titan Medical to Present at the H.C. Wainwright Global Investment Conference TORONTO-(BUSINESS WIRE)-May 18, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos? robotic single access surgical system at the H.C. Wainwright Global I |
|
| May 12, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Paul Cataford, Interim President and Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations |
|
| May 12, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Stephen Lemieux, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations: Based on my knowle |
|
| May 12, 2022 |
TITAN MEDICAL INC. 2022 First Quarter Condensed Interim Consolidated Financial Statements Exhibit 99.2 ? TITAN MEDICAL INC. 2022 First Quarter Condensed Interim Consolidated Financial Statements (Unaudited) TITAN MEDICAL INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited) (in thousands of US dollars) Notes As at March 31, 2022 As at December 31, 2021 ASSETS CURRENT ASSETS Cash and cash equivalents $ 30,112 $ 32,306 Accounts receivable - 8,280 Prepaid expens |
|
| May 12, 2022 |
Exhibit 99.1 Titan Medical Reports Financial Results for the First Quarter 2022 Manufacturing Team and Capabilities Continue to Expand TORONTO, May 12, 2022 - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced financial results fo |
|
| May 12, 2022 |
TITAN MEDICAL INC. Discussion and Analysis for the three months ended March 31, 2022 May 11, 2022 Exhibit 99.3 TITAN MEDICAL INC. Management?s Discussion and Analysis for the three months ended March 31, 2022 May 11, 2022 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 OVERVIEW 4 SIGNIFICANT TRANSACTIONS 5 ENOS SINGLE ACCESS ROBOTIC ASSISTED SURGICAL SYSTEM 7 INTELLECTUAL PROPERTY AND LICENSING 12 RESULTS OF OPERATIONS 13 FINANCIAL POSITION 15 LIQUIDITY |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executiv |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executiv |
|
| May 6, 2022 |
Exhibit 99.1 Titan Medical Announces Availability of Materials for the 2022 Annual and Special Meeting of Shareholders TORONTO-(BUSINESS WIRE)-May 6, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that its 2022 Annual and |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal executiv |
|
| May 3, 2022 |
Titan Medical Announces Purchase Order from Medtronic Exhibit 99.1 Titan Medical Announces Purchase Order from Medtronic TORONTO-(BUSINESS WIRE)-May 3, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced receipt of a $2.6 million purchase order from Medtronic plc (NYSE: MDT), a g |
|
| April 28, 2022 |
Titan Medical to Issue First Quarter 2022 Financial Results on May 12, 2022 Exhibit 99.1 Titan Medical to Issue First Quarter 2022 Financial Results on May 12, 2022 TORONTO-(BUSINESS WIRE)-April 28, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its first quarter 2022 financial results prior to market opening on Thursday, May 12, 2022. I |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execut |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execut |
|
| April 26, 2022 |
Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference Exhibit 99.1 Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference TORONTO-(BUSINESS WIRE)-April 26, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos? robotic single access surgical system at the Bloom Burton & Co |
|
| March 24, 2022 |
Consent of BDO Canada LLP, Chartered Professional Accountants and Licensed Public Accountants Exhibit 15.3 Consent of Independent Registered Public Accounting Firm Titan Medical Inc. Toronto, Canada We hereby consent to the use of our report dated March 23, 2022, relating to the financial statements of Titan Medical Inc. (the ?Company?) included in this Annual Report on Form 20-F for the year ended December 31, 2021. We also consent to the incorporation by reference of such reports into th |
|
| March 24, 2022 |
Certificate of Principal Executive Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Titan Medical Inc. (the ?Company?) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Paul Cataford, Interim President and Chief Executive Offi |
|
| March 24, 2022 |
Exhibit 2.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 20-F of which this Exhibit 2.1 is a part, Titan Medical Inc. (the ?Company?, ?we?, ?us? or ?our?) has only one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: the Company?s com |
|
| March 24, 2022 |
Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) Exhibit 12.2 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Stephen Lemieux, certify that: 1. I have reviewed this annual report on Form 20-F of Titan Medical Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 |
|
| March 24, 2022 |
Certificate of Principal Financial Officer pursuant to 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Titan Medical Inc. (the “Company”) on Form 20-F for the period ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stephen Lemieux, Chief Financial Officer of the Company, |
|
| March 24, 2022 |
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) Exhibit 12.1 CERTIFICATION REQUIRED BY RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 I, Paul Cataford, certify that: 1. I have reviewed this annual report on Form 20-F of Titan Medical Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances u |
|
| March 24, 2022 |
Exhibit 4.1 TITAN MEDICAL INC. STOCK OPTION PLAN (Amended and Restated effective as of June 9, 2021) 1. The Plan and Definitions A stock option plan (this ?Plan?), pursuant to which options to purchase common shares in the capital of Titan Medical Inc. (the ?Corporation?) may be granted to the directors, officers and employees of the Corporation and to Service Providers retained by the Corporation |
|
| March 24, 2022 |
Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021 Exhibit 99.1 Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021 Completed Final Milestone with Medtronic Selected Benchmark to Manufacture Enos System Expanded Patent Portfolio to More Than 200 TORONTO-(BUSINESS WIRE)-March 24, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of i |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execut |
|
| March 24, 2022 |
Management’s discussion and analysis of the Company for the year ended December 31, 2021 EX-15.1 9 ex15-1.htm MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE COMPANY FOR THE YEAR ENDED DECEMBER 31, 2021 Exhibit 15.1 TITAN MEDICAL INC. Management’s Discussion and Analysis for the year ended December 31, 2021 March 23, 2022 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 OVERVIEW 4 SIGNIFICANT TRANSACTIONS 5 ENOS ROBOTIC SINGLE ACCESS SURGICAL SYSTEM |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execut |
|
| March 14, 2022 |
Titan Medical to Report Year End 2021 Financial Results on March 24, 2022 Exhibit 99.1 Titan Medical to Report Year End 2021 Financial Results on March 24, 2022 TORONTO-(BUSINESS WIRE)-March 14, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its year end 2021 financial results prior to market opening on Thursday, March 24, 2022. In add |
|
| March 8, 2022 |
Titan Medical to Present at the Oppenheimer 32nd Annual Healthcare Conference Exhibit 99.1 Titan Medical to Present at the Oppenheimer 32nd Annual Healthcare Conference TORONTO-(BUSINESS WIRE)-March 8, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced the company will present an overview of its Enos? robotic single access surgical system at Oppenheimer?s 32nd Annual Healthc |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal execut |
|
| February 7, 2022 |
6-K 1 a52574671.htm TITAN MEDICAL INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontar |
|
| February 7, 2022 |
EX-99.1 2 a52574671ex991.htm EXHIBIT 99.1 Exhibit 99.1 Titan Medical Expands Patent Portfolio to More Than 200 Patents and Applications and Clarifies Third-Party Licensing Strategy TORONTO-(BUSINESS WIRE)-February 7, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robot |
|
| January 26, 2022 |
Titan Medical Receives Final Milestone Payment and Retires Senior Secured Loan From Medtronic Exhibit 99.1 Titan Medical Receives Final Milestone Payment and Retires Senior Secured Loan From Medtronic TORONTO-(BUSINESS WIRE)-January 26, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the design and development of innovative surgical technologies for robotic single access surgery, announced today that it has received payment from Medtronic plc after |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exec |
|
| January 11, 2022 |
Titan Medical Selects Benchmark to Manufacture Enos Robotic Single Access Surgical System Exhibit 99.1 Titan Medical Selects Benchmark to Manufacture Enos Robotic Single Access Surgical System TORONTO-(BUSINESS WIRE)-January 11, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the design and development of innovative surgical technologies for robotic single access surgery, announced today that it has signed a manufacturing and supply agreement w |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exec |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exec |
|
| January 5, 2022 |
Titan Medical to Participate in H.C. Wainwright BioConnect 2022 Virtual Investor Conference EX-99.1 2 a52557756ex991.htm EXHIBIT 99.1 Exhibit 99.1 Titan Medical to Participate in H.C. Wainwright BioConnect 2022 Virtual Investor Conference TORONTO-(BUSINESS WIRE)-January 5, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced tod |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 76 Berkely Street Toronto, Ontario M5A 2W7 Canada (Address of principal exec |
|
| January 4, 2022 |
Titan Medical Completes Final Milestone Under Development Agreement with Medtronic Exhibit 99.1 Titan Medical Completes Final Milestone Under Development Agreement with Medtronic TORONTO-(BUSINESS WIRE)-January 4, 2022-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced today that it completed, on schedule, the final milest |
|
| December 30, 2021 |
Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency TORONTO-(BUSINESS WIRE)-December 30, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, today received notification from the Nasdaq Stock Market LLC Lis |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address o |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address |
|
| December 2, 2021 |
Titan Medical Announces CEO Transition Exhibit 99.1 Titan Medical Announces CEO Transition TORONTO-(BUSINESS WIRE)-December 1, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, announced that President and Chief Executive Officer David McNally has stepped down as President and CEO, and resigned f |
|
| November 12, 2021 |
Exhibit 99.1 Titan Medical Reports Third Quarter 2021 Financial Results Expanded Surgeon Advisory Board Completed GLP Studies Enos System Commercial Launch Timeline Update TORONTO, November 11, 2021 - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of its innovative surgical technologies for robotic-assisted surgery that re |
|
| November 12, 2021 |
Exhibit 99.3 TITAN MEDICAL INC. Management?s Discussion and Analysis for the three and nine months ended September 30, 2021 November 11, 2021 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 NON-IFRS FINANCIAL MEASURES 4 OVERVIEW 5 SIGNIFICANT TRANSACTIONS 6 ENOS ROBOTIC SINGLE ACCESS SURGICAL SYSTEM 10 INTELLECTUAL PROPERTY AND LICENSING 18 RESULTS OF OPERAT |
|
| November 12, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Stephen Lemieux, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended September 30, 2021. 2. No misrepresentations: Based on my kn |
|
| November 12, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, David McNally, Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended September 30, 2021. 2. No misrepresentations: Based on my know |
|
| November 12, 2021 |
TITAN MEDICAL INC. 2021 Third Quarter Condensed Interim Consolidated Financial Statements Exhibit 99.2 ? TITAN MEDICAL INC. 2021 Third Quarter Condensed Interim Consolidated Financial Statements (Unaudited) TITAN MEDICAL INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited) (In thousands of US Dollars) Note September 30, 2021 December 31, 2020 Assets Current assets: Cash $ 44,677 $ 25,469 Prepaid expenses, deposits and receivables 1,702 1,479 46,379 26,948 No |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021. Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address |
|
| November 3, 2021 |
Titan Medical Announces Expansion of Surgeon Advisory Board Exhibit 99.1 Titan Medical Announces Expansion of Surgeon Advisory Board Additions to Surgeon Advisory Board support planned clinical studies TORONTO-(BUSINESS WIRE)-November 3, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced changes |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address o |
|
| November 1, 2021 |
Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021 Exhibit 99.1 Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021 TORONTO-(BUSINESS WIRE)-November 1, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery today announced that the company plans to issue its third quarter 2021 |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address o |
|
| October 25, 2021 |
Titan Medical Announces Completion of Pre-Clinical GLP Studies EX-99.1 2 a52514230ex991.htm EXHIBIT 99.1 Exhibit 99.1 Titan Medical Announces Completion of Pre-Clinical GLP Studies TORONTO-(BUSINESS WIRE)-October 25, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed its scheduled pre-clinical studies |
|
| October 25, 2021 |
6-K 1 a52514230.htm TITAN MEDICAL INC. FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite |
|
| September 14, 2021 |
Titan Medical to Participate in Upcoming Investor Conferences in September Exhibit 99.1 Titan Medical to Participate in Upcoming Investor Conferences in September TORONTO-(BUSINESS WIRE)-September 14, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, wil |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of Sept 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pr |
|
| September 7, 2021 |
Titan Medical to Participate in H.C. Wainwright Investor Conference Exhibit 99.1 Titan Medical to Participate in H.C. Wainwright Investor Conference TORONTO-(BUSINESS WIRE)-September 7, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will presen |
|
| September 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of Sept 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pr |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, David McNally, Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended June 30, 2021. 2. No misrepresentations: Based on my knowledge |
|
| August 11, 2021 |
TITAN MEDICAL INC. 2021 Second Quarter Condensed Interim Consolidated Financial Statements Exhibit 99.2 ? TITAN MEDICAL INC. 2021 Second Quarter Condensed Interim Consolidated Financial Statements (Unaudited) TITAN MEDICAL INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited) (In thousands of US Dollars) Note June 30, 2021 December 31, 2020 Assets see Note 1(b) Current assets: Cash $ 55,005 $ 25,469 Prepaid expenses, deposits and receivables 1,905 1,479 56,910 |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Stephen Lemieux, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended June 30, 2021. 2. No misrepresentations: Based on my knowled |
|
| August 11, 2021 |
Exhibit 99.1 Titan Medical Reports Second Quarter 2021 Financial Results Achievement of milestone and receipt of $10 million license payment from Medtronic Augmented Board of Directors and strengthened leadership team Progress on development activities to support submission of IDE application to FDA TORONTO, August 11, 2021 - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company fo |
|
| August 11, 2021 |
Exhibit 99.3 TITAN MEDICAL INC. Management?s Discussion and Analysis for the three and six months ended June 30, 2021 August 10, 2021 Table of Contents INTRODUCTION 3 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 NON-IFRS FINANCIAL MEASURES 4 OVERVIEW 4 SIGNIFICANT TRANSACTIONS 5 ENOS ROBOTIC SINGLE ACCESS SURGICAL SYSTEM 9 INTELLECTUAL PROPERTY AND LICENSING 14 RESULTS OF OPERATIONS 15 L |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021. Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, OntarioM5H 3B7 Canada (Address of |
|
| August 3, 2021 |
Titan Medical to Report Second Quarter 2021 Financial Results on August 11, 2021 Exhibit 99.1 Titan Medical to Report Second Quarter 2021 Financial Results on August 11, 2021 TORONTO-(BUSINESS WIRE)-August 3, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of |
|
| August 2, 2021 |
Exhibit 99.1 Titan Medical Announces Appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs TORONTO-(BUSINESS WIRE)-August 2, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Tammy Carrea as Vice President of Quality |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pr |
|
| July 22, 2021 |
Titan Medical to Participate in Alliance Global Partners Virtual MedTech Summer Investor Conference Exhibit 99.1 Titan Medical to Participate in Alliance Global Partners Virtual MedTech Summer Investor Conference TORONTO-(BUSINESS WIRE)-July 22, 2021-Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, and Stephen |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pr |
|
| July 12, 2021 |
Titan Medical Announces Appointment of New Chief Financial Officer Exhibit 99.1 Titan Medical Announces Appointment of New Chief Financial Officer TORONTO-(BUSINESS WIRE)-July 12, 2021-Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Stephen Lemieux as the Chief Financial Officer of the Company. Mr. Lemieux has mo |
|
| June 10, 2021 |
Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders Exhibit 99.1 Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders Welcomes Cathy Steiner as Independent Director TORONTO-(BUSINESS WIRE)-June 10, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the voting results from the compa |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pr |
|
| May 28, 2021 |
Exhibit 99.1 Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development Agreement Completion of Second Technical Milestone Marks Third Achievement Under Development and License Agreement May 28, 2021. TORONTO - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for rob |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38524 Titan Medical Inc. (Translation of registrant's name into English) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of princi |
|
| May 24, 2021 |
EXHIBIT 99.1 Titan Medical Announces Addition of Deepak Basra as Vice President, Strategy and Business Development TORONTO, May 24, 2021 (GLOBE NEWSWIRE) - Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the addition of Deepak Basra as Vice President, Strategy and |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38524 Titan Medical Inc. (Translation of registrant's name into English) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of princi |
|
| May 19, 2021 |
Titan Medical to Present at Oppenheimer MedTech Summit Investor Conference Exhibit 99.1 Titan Medical to Present at Oppenheimer MedTech Summit Investor Conference TORONTO-(BUSINESS WIRE)-May 19, 2021-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the com |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pri |
|
| May 18, 2021 |
Exhibit 99.2 |
|
| May 18, 2021 |
Exhibit 99.1 155 University Avenue, Suite 750 Toronto, Ontario, Canada M5H 3B7 ? Tel: 416.548.7522 [email protected] ? www.titanmedicalinc.com NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 9, 2021 - AND - MANAGEMENT INFORMATION CIRCULAR DATED MAY 13, 2021 These materials are important and require your immediate attention. They require shareholders of Titan Medical |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2021. Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of p |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2021. Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, OntarioM5H 3B7 Canada (Address of pr |
|
| May 17, 2021 |
TITAN MEDICAL INC. Discussion and Analysis for the three months ended March 31, 2021 May 15, 2021 EX-99.3 4 e13364ex99-3.htm MD&A - MARCH 31, 2021 Exhibit 99.3 TITAN MEDICAL INC. Management’s Discussion and Analysis for the three months ended March 31, 2021 May 15, 2021 Table of Contents Introduction 3 COVID - 19 Pandemic 3 Internal Control over Financial Reporting 4 Cautionary Note Regarding Forward-Looking Statements 4 Development Agreement & License Agreement with Medtronic 8 Senior Secured |
|
| May 17, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Monique L. Delorme, Chief Financial Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended March 31, 2021. 2. No misrepresentations: Based on my kno |
|
| May 17, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, David McNally, Chief Executive Officer of Titan Medical Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Titan Medical Inc. (the ?issuer?) for the interim period ended March 31, 2021. 2. No misrepresentations: Based on my knowledg |
|
| May 17, 2021 |
Exhibit 99.1 Titan Medical Reports First Quarter 2021 Financial Results and Provides Board Update Paul Cataford Appointed Chairman of the Board Heather Knight Appointed as Independent Director Cathy Steiner Nominated for Election as Independent Director May 17, 2021. TORONTO-(BUSINESS WIRE)-Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development |
|
| May 17, 2021 |
TITAN MEDICAL INC. 2021 First Quarter Condensed Interim Consolidated Financial Statements Exhibit 99.2 ? TITAN MEDICAL INC. 2021 First Quarter Condensed Interim Consolidated Financial Statements (Unaudited) TITAN MEDICAL INC. Condensed Interim Consolidated Statements of Financial Position (Unaudited) (In thousands of US Dollars) Note March 31, 2021 December 31, 2020 Assets see Note 1(b) Current assets: Cash and cash equivalents $ 53,370 $ 25,469 Prepaid expenses and deposits 2,460 1,47 |
|
| May 11, 2021 |
Current Report of Foreign Issuer - TITAN MEDICAL INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of pri |
|
| May 11, 2021 |
Titan Medical to Report First Quarter 2021 Financial Results May 17, 2021 Exhibit 99.1 Titan Medical to Report First Quarter 2021 Financial Results May 17, 2021 TORONTO-(BUSINESS WIRE)-May 4, 2021-Titan Medical Inc. (?Titan? or the ?Company?) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company plans to issue its first quarter financial results pri |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Titan Medical Inc. (Exact name of registrant as specified in its charter) Ontario, Canada 98-0663504 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Cana |
|
| April 22, 2021 |
Current Report of Foreign Issuer - TITAN MEDICAL INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of p |
|
| April 22, 2021 |
Exhibit 99.1 TITAN MEDICAL EXPANDS SENIOR LEADERSHIP TEAM Kristen Galfetti Appointed as Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President, Finance April 22, 2021, TORONTO-(BUSINESS WIRE)-Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for ro |
|
| April 16, 2021 |
TITAN MEDICAL INC. SHARE UNIT PLAN ARTICLE 1 RECITALS Exhibit 99.2 TITAN MEDICAL INC. SHARE UNIT PLAN ARTICLE 1 RECITALS 1.1 Purpose. Titan Medical Inc. (together with any successor thereto, the ?Corporation?) wishes to establish this Titan Medical Inc. Share Unit Plan (the ?Plan?) in order to: (a) encourage selected Eligible Employees and Service Providers of the Corporation and its Affiliates to: (i) acquire a proprietary interest in the growth and |
|
| April 16, 2021 |
TITAN MEDICAL INC. DEFERRED SHARE UNIT PLAN ARTICLE 1 INTRODUCTION Exhibit 99.3 TITAN MEDICAL INC. DEFERRED SHARE UNIT PLAN ARTICLE 1 INTRODUCTION 1.1 Purpose The purpose of this Deferred Share Unit Plan is to provide directors of Titan Medical Inc. (the ?Corporation?) with the opportunity to acquire Deferred Share Units (as defined herein) of the Corporation in order to allow them to participate in the long-term success of the Corporation and to promote a greate |
|
| April 16, 2021 |
Current Report of Foreign Issuer - TITAN MEDICAL INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2021. Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of |
|
| April 16, 2021 |
TITAN MEDICAL INC. STOCK OPTION PLAN (Amended and Restated effective as of October 20, 2020) Exhibit 99.1 TITAN MEDICAL INC. STOCK OPTION PLAN (Amended and Restated effective as of October 20, 2020) 1. The Plan and Definitions A stock option plan (this ?Plan?), pursuant to which options to purchase common shares in the capital of Titan Medical Inc. (the ?Corporation?) may be granted to the directors, officers and employees of the Corporation and to Service Providers retained by the Corpor |
|
| April 5, 2021 |
Current Report of Foreign Issuer - TITAN MEDICAL INC. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-38524 Titan Medical Inc. (Exact Name of Registrant as Specified in Charter) 155 University Avenue, Suite 750 Toronto, Ontario M5H 3B7 Canada (Address of p |
|
| April 5, 2021 |
Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference Exhibit 99.1 Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference TORONTO-(BUSINESS WIRE)-April 5, 2021-Titan Medical Inc. (?Titan? or the ?Company?) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Me |
|
| April 1, 2021 |
Management’s Discussion and Analysis dated February 20, 2021 for the year ended December 31, 2020 Exhibit 99.3 TITAN MEDICAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2020 (IN UNITED STATES DOLLARS) This Management?s Discussion and Analysis (?MD&A?) is dated February 20, 2021. Introduction This MD&A provides a review of the performance of Titan Medical Inc. (?Titan? or the ?Company?) and should be read in conjunction with its audited financial statements for the |
|
| April 1, 2021 |
Audited Consolidated Financial Statements for the years ended December 31, 2020 and 2019 Exhibit 99.2 TITAN MEDICAL INC. Consolidated Financial Statements Years Ended December 31, 2020, and 2019 (IN UNITED STATES DOLLARS) Tel: 416 865 0200 Fax: 416 865 0887 www.bdo.ca BDO Canada LLP 222 Bay Street Suite 2200, PO Box 131 Toronto ON M5K 1H1 Canada Report of Independent Registered Public Accounting Firm Shareholders of Titan Medical Inc. Toronto, Ontario Opinion on the Consolidated Finan |
|
| April 1, 2021 |
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. ?1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Titan Medical Inc. (the ?Company?) on Form 40-F for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Monique L. Delorme, Chief Financial Officer of the Compan |
|
| April 1, 2021 |
Exhibit 99.8 Consent of Independent Registered Public Accounting Firm Titan Medical Inc. Toronto, Canada We hereby consent to the use of our report dated February 20, 2021, on the financial statements of Titan Medical Inc. (the ?Company?) for the years ended December 31, 2020 and 2019 included in this annual report on Form 40-F. We also consent to the incorporation by reference of such reports int |
|
| April 1, 2021 |
Annual Information Form dated March 31, 2021 for the fiscal year ended December 31, 2020 Exhibit 99.1 ANNUAL INFORMATION FORM For the fiscal year ended December 31, 2020 March 31, 2021 TITAN MEDICAL INC. ANNUAL INFORMATION FORM TABLE OF CONTENTS CORPORATE STRUCTURE 1 Name, Address, and Incorporation 1 Intercorporate Relationships 1 Currency 1 CAUTION REGARDING FORWARD?LOOKING STATEMENTS 1 DEVELOPMENT OF THE BUSINESS 5 Three Year History 5 DESCRIPTION OF THE BUSINESS 15 Product Develop |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Commission File Number 001-38524 TITAN MEDICAL INC. (Exact name of Registrant as specified in its |
|
| April 1, 2021 |
Exhibit 99.5 CERTIFICATION I, Monique L. Delorme, certify that: 1. I have reviewed this annual report on Form 40-F of Titan Medical Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec |
|
| April 1, 2021 |
Exhibit 99.4 CERTIFICATION I, David McNally, certify that: 1. I have reviewed this annual report on Form 40-F of Titan Medical Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to |
|
| April 1, 2021 |
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EX-99.6 7 a52403650ex996.htm EXHIBIT 99.6 Exhibit 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. §1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Titan Medical Inc. (the “Company”) on Form 40-F for the period ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David McNally, |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 16, 2021 |
Titan Medical Issues Corporate Update Exhibit 99.1 Titan Medical Issues Corporate Update Large market opportunity, strong corporate foundation, innovative robotic-assisted technology Clinical studies expected to commence in 2022 TORONTO-(BUSINESS WIRE)-March 9, 2021-Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for roboti |
